Post by
24minus7 on Jun 26, 2022 4:24am
@PRC - Potential TFC-1067 - year 1-5
https://1drv.ms/x/s!AvRAHt7sXjA7g64TCBfGQtgwM0Humg?e=5P3cq1
Figures from year 4 onwards suggest that AbbVie/Allergan have not only been able to serve an existing market, but have also been able to create a new NEED after a high quality and high priced treatment method (skinlightening/dyschromia).
@PRC - I look forward to seeing your numbers next Monday.
Comment by
navajojoe on Jun 26, 2022 11:27am
This post has been removed in accordance with Community Policy
Comment by
Engcan77 on Jun 26, 2022 2:17pm
Pareto. What you just commented, was exactly what i thought also, but didn't want to ramble on.lol The upfront payment is important, because a few million upfront is more of an insentive to produce products, than pocket money of 50 grand from R+F. Supposedly Allargan spend quite a bit of cash to do their own testing on TFC-1067. That is a good sign also.